{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:44:13Z","timestamp":1789595053267,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11102-022-01244-w","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T16:02:32Z","timestamp":1656777752000},"page":"737-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cushing\u2019s disease: role of preoperative and primary medical therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Frederic","family":"Castinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"12","key":"1244_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1244_CR2","doi-asserted-by":"publisher","first-page":"bvac010","DOI":"10.1210\/jendso\/bvac010","volume":"6","author":"EV Varlamov","year":"2022","unstructured":"Varlamov EV, Vila G, Fleseriu M (2022) Perioperative management of a patient with cushing disease. J Endocr Soc 6(3):bvac010","journal-title":"J Endocr Soc"},{"issue":"9","key":"1244_CR3","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenicky","year":"2011","unstructured":"Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF et al (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 96(9):2796\u20132804","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1244_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-14-0913","volume":"172","author":"JB Corcuff","year":"2015","unstructured":"Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A (2015) Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol 172(4):473\u2013481","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1244_CR5","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/ERC-15-0541","volume":"23","author":"C Guerin","year":"2016","unstructured":"Guerin C, Taieb D, Treglia G, Brue T, Lacroix A, Sebag F et al (2016) Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism? Endocr Relat Cancer 23(2):R131\u2013R142","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1244_CR6","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-21-1008","volume":"186","author":"A Tabarin","year":"2022","unstructured":"Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey AC, Chabre O et al (2022) Efficacy and tolerance of osilodrostat in patients with Cushing\u2019s syndrome due to adrenocortical carcinomas. Eur J Endocrinol 186(2):K1\u2013K4","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1244_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.surg.2008.08.024","volume":"144","author":"RS Sippel","year":"2008","unstructured":"Sippel RS, Elaraj DM, Kebebew E, Lindsay S, Tyrrell JB, Duh QY (2008) Waiting for change: symptom resolution after adrenalectomy for Cushing\u2019s syndrome. Surgery 144(6):1054\u20131060","journal-title":"Surgery"},{"issue":"5","key":"1244_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D et al (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab 99(5):1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1244_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-17-0997","volume":"178","author":"E Valassi","year":"2018","unstructured":"Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S et al (2018) Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 178(4):399\u2013409","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1244_CR10","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","volume":"106","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Nieman LK, Reincke M, Newell-Price J (2021) Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab 106(7):2114\u20132123","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1244_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR et al (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol 182(2):207\u2013217","journal-title":"Eur J Endocrinol"},{"key":"1244_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cen14551","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Amodru V, Brue T (2021) Osilodrostat in Cushing\u2019s disease: the risk of delayed adrenal insufficiency should be carefully monitored. Clin Endocrinol. https:\/\/doi.org\/10.1111\/cen14551","journal-title":"Clin Endocrinol"},{"issue":"9","key":"1244_CR13","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1210\/jc.2019-00333","volume":"104","author":"J Cristante","year":"2019","unstructured":"Cristante J, Lefournier V, Sturm N, Passagia JG, Gauchez AS, Tahon F et al (2019) Why we should still treat by neurosurgery patients with Cushing\u2019s disease and a normal or inconclusive pituitary. MRI J Clin Endocrinol Metab 104(9):4101\u20134113","journal-title":"MRI J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01244-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01244-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T09:24:55Z","timestamp":1666430695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01244-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01244-w","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"16 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FC received research grants and consultancy fees from HRA Pharma and Recordati Rare Diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}